1. Home
  2. EPM vs MGNX Comparison

EPM vs MGNX Comparison

Compare EPM & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolution Petroleum Corporation Inc.

EPM

Evolution Petroleum Corporation Inc.

HOLD

Current Price

$4.49

Market Cap

158.2M

Sector

Energy

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.08

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPM
MGNX
Founded
2003
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
158.2M
115.8M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
EPM
MGNX
Price
$4.49
$3.08
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
$4.93
$3.40
AVG Volume (30 Days)
412.9K
1.3M
Earning Date
01-01-0001
06-15-2026
Dividend Yield
10.46%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$43,229,621.00
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$92.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$0.99
52 Week High
$5.70
$3.50

Technical Indicators

Market Signals
Indicator
EPM
MGNX
Relative Strength Index (RSI) 53.70 73.39
Support Level $4.38 $1.45
Resistance Level $4.63 $3.50
Average True Range (ATR) 0.16 0.22
MACD -0.02 0.10
Stochastic Oscillator 37.17 75.44

Price Performance

Historical Comparison
EPM
MGNX

About EPM Evolution Petroleum Corporation Inc.

Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: